Harvard Bioscience, Inc. President to Speak at the Thomas Weisel Partners Growth Forum 2001 Conference
HOLLISTON, Mass., June 20 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that David Green, President of Harvard Bioscience, will participate in a panel and make a presentation at the Thomas Weisel Partners, LLP Growth Forum 2001 Conference to be held June 24 - 27, 2001 in Santa Barbara, California.
Mr. Green will participate in the healthcare panel along with Mr. Paul Knight and Mr. David Lewis, of Thomas Weisel Partners. The panel discussion will be simultaneously broadcast over the internet at approximately 11am, Eastern Time, on June 26, 2001 and can be accessed at http://www.veracast.com/webcasts/twp/growth-forum-2001/77201118.cfm.
Later in the day, Mr. Green will present an overview of Harvard Bioscience, including its products and markets. He will also present the Company's business model and strategy. This event will be simultaneously broadcast over the internet at 7:30pm, Eastern Time, and can be found at http://www.veracast.com/webcasts/twp/growth-forum-2001/85212186.cfm.
In the panel and in his presentation, Mr. Green may answer questions concerning business and financial developments and trends, and other business and financial matters affecting Harvard Bioscience. Some responses to questions may contain information that has not previously been disclosed. Archives of both events will be available for 30 days after the conference through Veracast Communications, Inc.
Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells approximately 10,000 products to thousands of researchers in over 60 countries though its 1,000 page catalog, and through its distributors, the most notable of which is AP Biotech. HBIO has sales and manufacturing operations in the United States, the United Kingdom, and Germany with sales facilities in France and Canada.
SOURCE Harvard Bioscience, Inc.
CONTACT: Jim Warren, CFO, jwarren@harvardbioscience.com, or David Green, President, dgreen@harvardbioscience.com, or Chane Graziano, CEO, cgraziano@harvardbioscience.com, all of Harvard Bioscience/
Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.